The MeDIAGSTOLE project aims to develop diagnostic tools for heart failure with preserved ejection fraction (IC / FEp), a pathology that is difficult to diagnose and to manage clinically in the absence of targeted treatment . The IC / FEp concerns the elderly population with comorbidities such as hypertension, obesity, anemia and atrial fibrillation. In the absence of specific biomarkers, clinical diagnosis is based on serum markers of heart failure with reduced ejection fraction (IC / FEr). The identification of new biomarkers, genetic and / or cellular, specific for IC / FEp would be an important innovation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
diagnostic power of a multi-marker approach (progenitor cells)
Timeframe: At 12 months
diagnostic power of a multi-marker approach (monocytes)
Timeframe: At 12 months
diagnostic power of a multi-marker approach (NT-proBNP)
Timeframe: At 12 months
diagnostic power of a multi-marker approach (sST2)
Timeframe: At 12 months
diagnostic power of a multi-marker approach (PIIINP)
Timeframe: At 12 months